News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
190 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37441)
2025 (33090)
2026 (22869)
Month
January (2433)
February (2868)
March (3029)
April (3116)
May (3356)
June (2727)
July (2287)
August (2493)
September (560)
Day
1 (65)
3 (19)
4 (205)
5 (197)
6 (190)
7 (229)
8 (170)
10 (33)
11 (150)
12 (194)
13 (208)
14 (261)
15 (58)
17 (52)
18 (160)
19 (145)
20 (146)
21 (119)
22 (102)
24 (37)
25 (10)
26 (177)
27 (191)
28 (158)
29 (79)
31 (1)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
Day
1
3
4
5
6
7
8
10
11
12
13
14
15
17
18
19
20
21
22
24
25
26
27
28
29
31
Immunology and inflammation
Viridian turns green again as new Phase 3 data vindicate thyroid eye disease drug
Viridian Therapeutics’ elegrobart normalized the degree of eye protrusion and improved double vision in a Phase 3 study. The company plans to file for approval in the first quarter of 2027.
May 6, 2026
·
1 min read
·
Tristan Manalac
Inflammatory bowel disease
J&J pushes dual-antibody IBD therapy into Phase 3 despite mid-stage fails
Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative colitis.
May 6, 2026
·
2 min read
·
Tristan Manalac
Press Releases
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
May 6, 2026
·
7 min read
Press Releases
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
May 6, 2026
·
12 min read
Press Releases
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
May 6, 2026
·
4 min read
Press Releases
Medline Reports First Quarter 2026 Results
May 6, 2026
·
20 min read
Press Releases
Crescent Biopharma to Present at May 2026 Investor Conferences
May 6, 2026
·
1 min read
Press Releases
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
May 6, 2026
·
1 min read
Press Releases
Immusoft to Present Data Highlighting Positive Results from the World’s First Engineered B Cell in a Human Clinical Trial at ASGCT 2026
May 6, 2026
·
3 min read
Press Releases
CURE ALZHEIMER’S FUND PRESENTS THE 2026 JEFFREY L. MORBY PRIZE FOR EXCEPTIONAL RESEARCH
May 6, 2026
·
3 min read
Previous
13 of 19
Next
